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Abstract
Background: Breast cancer incidence rates are increasing at an alarming rate among Saudi Arabian females. Most
molecular genetic discoveries on breast cancer and other cancers have arisen from studies examining European
and American patients. However, possibility of specific changes in molecular signature among cancer patients of
diverse ethnic groups remains largely unexplored. We performed transcriptomic profiling of surgically-resected
breast tumors from 45 patients based in the Western region of Saudi Arabia using Affymetrix Gene 1.0 ST chip.
Pathway and biological function-based clustering was apparent across the tissue samples.
Results: Pathway analysis revealed canonical pathways that had not been previously implicated in breast cancer.
Biological network analysis of differentially regulated genes revealed that Fatty acid binding protein 4, adipocyte
(FABP4), adiponectin (ADIPOQ), and retinol binding protein 4 (RBP4) were most down regulated genes, sharing
strong connection with the other molecules of lipid metabolism pathway. The marked biological difference in the
signatures uncovered between the USA and Saudi samples underpins the importance of this study. Connectivity
Map identified compounds that could reverse an observed gene expression signature
Conclusions: This study describes, to our knowledge, the first genome-wide profiling of breast cancer from Saudi
ethnic females. We demonstrate the involvement of the lipid metabolism pathway in the pathogenesis of breast
cancer from this region. This finding also highlights the need for strategies to curb the increasing rates of
incidence of this disease by educating the public about life-style risk factors such as unhealthy diet and obesity.
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Background
Breast cancer (BC) is the most common cancer that affects
females worldwide and is the second most frequent cause
of cancer-related deaths among women in the United
States [1]. According to the National Cancer Registry in the
Kingdom of Saudi Arabia (KSA), BC was ranked as the
most prevalent form of cancer among females, accounting
for 25.1% of all newly diagnosed female cancers (5,205) in
the year 2009 [2]. The ASR was 22.7/100,000 for the female
population. While the median age at presentation is around
63 years in the United States and Western Europe, the
median age at presentation in the KSA is 48 years [2]. The
genetic variability between patients and tumors drive this
clinically heterogeneous disease [3]. Much of the knowledge
on the molecular genetics on BC and other cancers has
been resulting from examining European and US patients.
However, growing scientific knowledge suggests the likeli-
hood of variability in molecular signature between cancers
from patients of different ethnic groups. Clear differences
in the patterns of p53 mutations in BC were found between
Midwest US Caucasian, African- American, Austrian, and
Japanese women [4,5]. Besides, varying patterns and the
occurrence of germline mutations in BRCA1 and BRCA2
between ethnic groups were also reported [6]. Recently,
National Cancer Institute’s Surveillance, Epidemiology, and
End Results (SEER) program show that the age-adjusted
BC frequency among minority groups are significantly
lower than those among white women [7] Increase in BC
mortality was also found in African American women
when compared to white women [8]. All these differences
continue to be mostly unexplained [9]. Moreover, changes
in occurrence and clinical characteristics linked with ethni-
city or race has got only limited consideration [10]. The
current lack of measures to aid in stratifying BC treatment
indicates the necessity for a new methodology to formulate
better prognostication and therapy prediction. Although
the parameters such as histological grade, stage, and tumor
size are accepted as prognostic markers for BC [11], about
50% of the patients with ER-positive cancer fail on tamoxi-
fen treatment [12,13].
Transcriptomics approaches that allow screening of
thousands of genes in an experiment, has had a major
impact on BC research over the past 10 years [14] Sev-
eral groups have carried out gene expression profiling of
BC and classified clinically distinct subclasses of tumors
[14], hereditary BC [15], and treatment prediction [16].
Many microarray studies so far reported have led to the
discovery of several genes associated with BC. However,
most of the gene expression profiling studies has been
carried out mainly in the Caucasian population, and
inclusion of the non-Caucasian population has been
minimal [17,18]. Significant risk factors of BC in the
western countries such as nulliparity, low parity, first
time pregnancy at late age, having no history of breast
feeding, etc., are usually not practiced in the Saudi
society, yet BC incidence is still high among women
from the KSA [19]. In addition, a study of Taiwanese
population reported that women who had more than
three full-term pregnancies; first full-term pregnancy at
the age of below 30; and three or more years of breast
feeding showed significantly reduced risk of BC [20].
These studies suggest that there is an important need to
better understand the molecular mechanisms underlying
BC from different populations. In view of the existence of
genetic differences across regional or geographical loca-
tions, more data specific to indigenous populations are
needed for comparative analysis of molecular changes in
breast tumors among Saudi population. More comprehen-
sive molecular and genomic analyses of breast cancers are
important to understand the complexity and severity of
the disease and to find ‘druggable’ molecular targets for
the development effective treatments. In order to obtain
relevant target genes associated with BC patients in the
KSA, we aim to start comprehensive microarray-based
gene expression profiling study of BC in the Kingdom.
Transcriptomic analysis coupled with functional and path-
way analysis could lead to new insight into biomarkers
and signatures associated with the disease. Deregulated
signaling pathways are thought to drive functional pro-
cesses such as cell growth, cellular proliferation, and inva-
sion of cancer cells. Thus, identifying such underlying
driving changes will be vital for studies of tumor progres-
sion, for the identification of novel therapeutic targets.
To this end, this study aimed to survey the genes that are
differentially regulated in forty five freshly frozen BC tissue
samples compared to eight normal controls. The ethnic
group of the cohort in this study provides unique dimen-
sion to BC research. We examined genome-wide gene
expression in order to elucidate the molecular mechanisms
underlying malignancy in breast tissues. Based on the dif-
ferential expression signature, we found biological func-
tions and pathways that are significantly altered in BC.
Pathway-based clustering was apparent across the tissue
samples. Pathway analysis revealed canonical pathways that
have not been implicated in BC, previously. We also
demonstrated additional utility of our BC signature by
comparative analysis between the USA and the KSA sam-
ples reveals marked biological differences in signature.
Furthermore, Connectivity Map (cmap) analysis offered
hypotheses regarding potential treatments for differential
regulation observed in the BC [21]. Thus, our finding
might open up new avenues of BC research and assist dis-
cover possible new targets for BC treatment where ethni-
city plays major role.
Results
The main focus of this study was to determine the tran-
scriptomic profiles of BC representing the Saudi society.
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To identify genes that are involved in BC development,
we analyzed the transcriptomic profiles of nearly 28,000
annotated genes. We profiled forty five fresh breast tis-
sue specimens and compared them with eight normal
control samples. We found 48 years as average age of
incidence for BC in Saudi Arabia. We also found that
73.3% of BC patients were either obese (n=25; 55.56%)
or over weight (n=8; 17.78% ) whereas only 26.7% were
normal weight (n=10) or under weight (n=2). We per-
formed PCA scatter plot for visualizing the high dimen-
sional array data. In the scatter plot, each point
represents a chip. We applied PCA for identifying out-
liers and major effects in the data. The results of PCA
of the transcriptomic data showed that the samples
from the same tissue type clustered tightly together.
Clear differences also observed between these cancer
and normal tissues revealing distinct expression profiles
for the different tissue types (Figure 1). PCA mapping
showed that 30% of the overall variance in the microar-
ray dataset is depicted by the first three principal
components.
Identification of differentially expressed genes
Comparison of the genome-wide expression of breast can-
cer revealed 1159 differentially expressed genes, 544 genes
of which were upregulated and 615 genes were downregu-
lated (2 fold change, false discovery rate p < 0.05).
As shown in Figure 2, unsupervised hierarchical clustering
revealed that the distinct gene-patterns between the two
tissue types. The other sample information including his-
topathology and age were also overlaid at the bottom of
the dendrogram. Cluster analysis also showed that the
cancer tissues agglomerated in various subsets according
to age, triple negative status and grade. Those of patients
with triple-negative breast cancer (TNBC), young age
(mean 41) and grade 3 tumor were clearly separated from
the old age (mean 50), grade 2 and non-TNBC. We also
investigated whether pathway based clustering is evident
in the gene signature. For this, genes from each signature
were extracted and analyzed for significantly altered biolo-
gical processes and pathways. Our results suggest that BC
patients, despite their histopathologic and age heterogene-
ity, were clustered into different groups defined by func-
tions and pathways.
Functional analysis of the breast cancer-associated genes
found an over expression of genes involved in cell cycle
progression, DNA repair, cell death, tumor morphology
and tissue developments. Specifically, genes that are known
to be associated with BC, including Topoisomerase 2 alpha
(TOP2A), Carcinoembryonic antigen-related cell adhesion
molecule 1 (CEACAM1), denticleless/RA-regulated nuclear
matrix associated protein (DTL), H3 histone family, mem-
ber A, histone 1, H3a (HIST1H3A), the targeting protein
for Xklp2 (TPX2), Hepatitis C virus NS5A-transactivated
protein (KIAA0101), centromere protein-F (CENPF) and
ubiquitin-conjugating enzyme E2T (UBE2T) were upregu-
lated compared to the controls. Furthermore, genes
associated with immune cell trafficking and interferon
signaling including chemokine (C-X-C motif) ligand 10
(CXCL10), matrix metallopeptidase 11(MMP11), inter-
feron, gamma-inducible protein 6 (IFI6), chemokine
(C-X-C motif) ligand 9 (CXCL9) and matrix metallopep-
tidase 9 and 13 (MMP9 and 13) were also significantly
upregulated. Interestingly, the biological process, cellu-
lar movement was significantly overrepresented in both
down-regulated and up-regulated gene lists pointing
that the metastasis was linked to a different equilibrium
of switching on and off.
Genes linked to lipid metabolism, drug metabolism,
and endocrine system development were significantly
down regulated in BC. The most downregulated genes
including Fatty acid binding protein 4, adipocyte
(FABP4), adiponectin (ADIPOQ), and retinol binding
protein 4 (RBP4) were known to be involved in lipid
metabolism. The downregulated genes also signify bio-
logical functions including cardiovascular system devel-
opment and function, small molecules biochemistry and
energy production. Both the functional and canonical
pathway analysis indicate that lipid metabolism is one
of the most disrupted and downregulated pathways
(Table 1; Figure 3).
Figure 1 Principal component analysis of transcriptomic data
set. Description: The top three principal components are plotted on
the X-, Y-, and Z-axes, respectively. Overall variation between cancer
and normal, where each spot represents an individual array, can be
seen by the clustering within each tissue type and the separation
between the different tissue types.
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Pathways and networks underlying breast cancer
To understand the mechanisms by which the genes alter
a wide range of physiological processes, we examined
molecular networks underlying BC. Transcriptomic sig-
natures showed significant disruption in signaling path-
ways associating genes of the glycerolipid metabolism,
ATM signaling, ILK signaling, DNA damage and cell
cycle (Table 1). Analysis by IPA shows a set of key genes
that disrupt a pathway such that it then results in tumor
initiation or progression. The pathway analysis revealed a
strong correlation between the transcriptomic signature
and the canonical glycerolipid metabolism which has not
been implicated in BC before. Majority of the genes
involved in the glycerolipid metabolism were downregu-
lated. These results further support the putative role of
these pathways in rendering BC susceptibility.
We further compared the genes involved in lipid meta-
bolism with recent data published from samples from the
USA by downloading publically available data of 16 infil-
trating ductal carcinoma (IDC) of the breast samples from
ArrayExpress accession E-GEO-D-22544(45) (Figure 4).
We chose IDC as it accounts for 80% of all breast cancers.
Figure 2 Functional analysis of altered gene expression data. Description: Dendrogram shows the change in expression levels of genes in
breast cancer compared to normal controls. Samples from each tissue were hybridized to Affymetrix Human ST 1.0 array and signals were
scanned after staining and washing the arrays. The data was analyzed as described in the ‘methods’ section, and analysis revealed differential
expression of 1159 genes. Agglomerative average-linkage hierarchical clustering for genes (Y axis) and tissue type (X axis) were obtained using
Partek GS 6.6 software. The cluster color represents the normalized expression level of a given gene in a particular tissue type or
histopathological condition given below and is colored according to the color bar at the bottom. Red denotes upregulation and blue denotes
downregulation according the color scale. Each column is single experiment from each subject and each row is a single gene. The data
represents 8 controls and 38 breast cancer samples. Seven samples with less information were removed from dendrogram. Yellow, pink and
green color boxes indicate cluster of relative differentially regulated genes and their significantly altered functions and pathways. Tumor grade,
ER, PR, HER2 and TNBC status were also included in the cluster. ‘1’ denotes +ve status and ‘0’denotes –ve status.
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Glycerolipid Metabolism 6.85E+00 1.36E-01 SDC1 (includes EG:20969),DGAT2,ADH1C (includes EG:11522),LIPE,GK,PNPLA2,
ADH1A,GPAM,PPAPDC1A,PPAPDC1B,AADAC,ALDH2,ALDH1A1,PPAP2A,ALDH1A3,
AGPAT2,ALDH1A2,LPL,ADH1B,MGLL,PPAP2C
Mitotic Roles of Polo-Like Kinase 5.26E+00 2.15E-01 KIF23,CDC25C,CDC20,PTTG1,PRC1 (includes EG:233406),CDC7 (includes EG:12545),
CCNB2,PLK1,CDK1,CCNB1,PLK4,ANAPC5,PPP2R1B,KIF11
Cardiac b-adrenergic Signaling 4.95E+00 1.36E-01 AKAP12,PDE2A,PLN,PPP1R1A,ADRBK2,ATP2A3,PPP1R14A,PDE1A,PDE1C,AKAP2/
PALM2-AKAP2,PRKAR2B,GNG11,PDE7B,PDE3B,PDE1B,MRAS,PDE8B,GNG2,PPP1CA,
PPP2R1B,APEX1
ATM Signaling 4.70E+00 2.22E-01 RAD51,CDC25C,SMC2,FANCD2,MAPK10,CCNB2,CREB3L4,MAPK13,CREB5,CDK1,
CHEK1,CCNB1
ILK Signaling 4.50E+00 1.30E-01 FN1,MYH11,CREB5,RHOH,KRT18,RHOU,FIGF,AKT3 (includes EG:10000),ACTG2,MUC1,
CFL1,FERMT2,PIK3C2G,RHOJ,CREB3L4,MYL9,RHOQ,RND3,FLNC,CFL2,ARHGEF6,
MAPK10,LEF1,PPP2R1B,MMP9




Leukocyte Extravasation Signaling 3.43E+00 1.15E-01 VAV2,RAC2,CLDN11,JAM2,PIK3C2G,GNAI1,MMP13,MAPK13,CLDN7,DLC1,ITGAL,
RHOH,TIMP4,CLDN4,CLDN8,EZR,CXCL12 (includes EG:20315),MAPK10,PECAM1,
MMP11,ACTG2,MMP9,CLDN3
Atherosclerosis Signaling 3.11E+00 1.22E-01 CMA1,CD36,MMP13,PLA2G2A,F3,APOC1,IL33,PLA2G4A,ALB,CXCL12 (includes
EG:20315),LPL,COL10A1,PDGFD,MMP9,APOD,RBP4
Glycolysis/Gluconeogenesis 2.98E+00 9.85E-02 PGK1,ADH1C (includes EG:11522), ALDH1L1, ALDH2, HK1,ADH1A ,ALDH1A1,
ALDH1A3,ALDH1A2,PGM5,ADH1B, ACSL1,ALDOC
Agrin Interactions at Neuromuscular
Junction
2.93E+00 1.59E-01 RAC2,PAK3,ARHGEF6,LAMA2,MRAS,MAPK10,ERBB3,ACTG2,ERBB2,ITGAL,EGFR
IL-8 Signaling 2.84E+00 1.04E-01 RAC2,ANGPT1,PIK3C2G,GNAI1,RHOJ,IRAK3,RHOH,CDH1,RHOQ,GNG11,RND3,
MAPK10,RHOU,MRAS,AKT3 (includes EG:10000),FIGF,GNG2,MMP9,ITGAX,EGFR
Inhibition of Angiogenesis by TSP1 2.65E+00 1.79E-01 TGFBR2,SDC1 (includes EG:20969),MAPK10,CD36,AKT3 (includes EG:10000),
MAPK13,MMP9
Interferon Signaling 2.65E+00 1.94E-01 OAS1,MX1,IRF9,STAT1,TAP1,BAK1,IRF1 (includes EG:16362)
Cell Cycle: G2/M DNA Damage
Checkpoint Regulation
2.60E+00 1.63E-01 CDC25C,CKS2,TOP2A,CCNB2,PLK1,CDK1,CHEK1,CCNB1
Cell Cycle Control of Chromosomal
Replication
2.52E+00 1.94E-01 MCM3,CDC45,CDC6 (includes EG:23834),CDC7 (includes EG:12545),MCM4,MCM7
Role of BRCA1 in DNA Damage
Response
2.47E+00 1.48E-01 RAD51,FANCD2,E2F5,BRCA2,PLK1,BRIP1,STAT1,BLM,CHEK1
Integrin Signaling 2.47E+00 1.00E-01 RAC2,CAPN6,TSPAN7,PIK3C2G,RHOJ,ITGAL,TTN (includes EG:22138), RHOH,MYL9,
RHOQ, TLN2,PAK3, RND3,TSPAN1,CAV1,MRAS,RHOU,AKT3 (includes EG:10000),
ACTG2 ,ITGA7, ITGAX
RhoGDI Signaling 2.39E+00 9.45E-02 CFL1,GNAI1,RHOJ,DLC1,RHOH,MYL9,CDH2,CDH1,RHOQ,GNG11,PAK3,RND3,EZR,
CFL2,ARHGEF6,MRAS,RHOU,ACTG2,GNG2
Production of Nitric Oxide and Reactive
Oxygen Species in Macrophages
2.34E+00 9.05E-02 PIK3C2G,PPP1R14A,RHOJ,MAPK13,RHOH,IRF1 (includes EG:16362), APOC1, ALB,
RHOQ, RND3,CAT,RHOU,MAPK10,AKT3 (includes EG:10000),STAT1,PPP1CA,
PPP2R1B,APOD,RBP4
Hereditary Breast Cancer Signaling 2.29E+00 1.09E-01 CDC25C,HDAC1,PIK3C2G,CDK1,CHEK1,CCNB1,RAD51,FANCD2,MRAS,AKT3 (includes
EG:10000),POLR2H,BRCA2,BLM,UBC




1.77E+00 1.14E-01 HSD17B13,IGF1,MRAS,PIK3C2G,AKT3 (includes EG:10000),CREB3L4,CREB5,EGFR
HER-2 Signaling in Breast Cancer 1.21E+00 9.88E-02 CCNE2,MRAS,PIK3C2G,PARD6B,AKT3 (includes EG:10000),ERBB3,ERBB2,EGFR
Breast Cancer Regulation by Stathmin1 7.29E-01 6.67E-02 CCNE2,GNAI1,PIK3C2G,PPP1R14A,CDK1,GNG11,PRKAR2B,ARHGEF6,E2F5,MRAS,
TUBA1C,GNG2,PPP1CA,PPP2R1B
The table shows the significantly overrepresented canonical pathways across the whole dataset of differentially expressed genes.
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Therapeutic suggestions using the Connectivity Map
Transcriptomic approaches for studying BC may be use-
ful as it can help to identify pathways that are signifi-
cantly altered in the specific population or an individual.
Moreover, it will allow us to determine specific, effective
drugs from the existing database. Having established the
feasibility of the computational approaches, we further
tried to distinguish compounds that can potentially
antagonize the effects of the molecular signature of BC
identified in this cohort. Cmap assesses the role of small
molecules and genetic effects on transcriptome and
establishes links between gene expression signatures and
drugs. Based on the connectivity score, we identified 13
selected compounds with average connectivity scores
less than -0.7, indicating a high negative correlation
(Table 2). Interestingly, five drugs including Fulvestrant,
Methotrexate, Letrozole, Doxorubicin and Tamoxifen
were FDA approved BC drugs. The compounds that
possibly would reverse observed BC signature and hence
potential candidates for further in vitro validation com-
prise Hydrocortisone, Gliclazide and Gliclazide. Hydro-
cortisone and Gliclazide are used for aiding in fat
metabolism and as anti-diabetic, respectively.
Discussion
Breast cancer therapeutic strategies today are generally
based on histopathological characterization, tumor size,
grading, and axillary lymph node and receptor status [1].
Even so, patients when diagnosed with similar conditions
and when treated with similar drug can go through exten-
sive differences in the development and relapse of BC.
Studies show that women, who had a full-term pregnancy
at an age below 30; and who went through three full-term
pregnancies, and three or more years of breast feeding,
were significantly protected against BC [20]. However, BC
incidence is high among women from the KSA. BC risk
factors including nulliparity or low parity, first full term
pregnancy at very late age, no breast feeding etc., are not
common in the Saudi society [19]. These factors combined
with the early onset of BC among women, in this ethnicity,
prompted us to study the molecular mechanism underly-
ing the malignancies.
In the present study, we identified transcriptomic sig-
nature in BC from the KSA that is associated with clinical
and histological parameters. The ethnicity of this cohort
renders the power to prospectively examine, the roles of
lifestyle and genetic susceptibility in the onset of BC. The
genome-wide expression analysis contains several overre-
presented functional gene classes and has substantial
overlaps with transcriptomic signatures of metastatic
human BC. The commonalities found between different
populations in terms of increased cell cycle regulation
and DNA integrity checkpoints were observed. A similar
transcriptomic signature for many of these genes has
been reported for human BC before [22-26].
Genes associated with lipid metabolism and small mole-
cule biochemistry was significantly downregulated in the
BC tissues. The role of these genes on the tumorigenesis
Figure 3 Molecular and cellular functions deregulated in breast cancer. Description: Functions are sized by -log (p-value), which shows the
associated log of the calculated p-value. Larger squares indicate highly significant overlap between the genes perturbed in the dataset and the
biological function or disease. The functions are colored by z-score. The color shows the direction of change for the function, based on the
regulation z-score: The positive (orange) score denotes that the biological process or disease is trending towards an increase and the negative
(blue) score denotes that the biological process or disease is trending towards a decrease.
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of BC has been reported previously [27-29]. Disruption of
lipid metabolism has been implicated in tumorigenesis in
several studies, especially in cancer of breast [30,31]. The
differential regulation of lipid metabolism between normal
and cancer subjects might reveal transformation in the
metabolism of the cancer patient in this ethnicity [31].
Decreased ADIPOQ levels interrupt cellular signaling net-
works that are linked to cell survival, angiogenesis, prolif-
eration, and cell-cycle regulation [32]. Adipose tissues
secrete ADIPOQ and LEP-ADIPOQ axis has been well
implicated in breast cancer tumorigenesis [32]. Levels of
ADIPOQ have been inversely correlated with obesity.
Figure 4 Comparison of lipid metabolism genes and their expression levels between KSA and USA breast cancer data. Description:
Gene expression data from both the present study as well data from Hawthorn et al were imported into IPA. Significantly altered biological
functions and pathways were obtained individually for each study. From the differentially expressed genes, those involved in lipid metabolism
were linked, and their expression levels were overlaid on to the network. a. KSA data; b. USA data. Molecules colored with green denote
downregulation and white denote no change in expression compared to their respective healthy normal.






Hydrocortisone -0.97 Alimentary tract and metabolism (Aid in fat, protein and carbohydrate metabolism)
Fulvestrant * -0.952 Estrogen receptor antagonist
Gliclazide -0.934 Potent antiatherogenic effect in type 2 diabetes
Deoxycortone -0.917 Corticosteroids for systemic use
Sirolimus -0.909 Antineoplastic and immunomodulating agents
Glimepiride -0.905 Sulfonylurea anti-diabetic drug
Repaglinide -0.895 Treatment of type II diabetes
Methotrexate * -0.89 Treatment of a number of cancers including breast
Letrozole * -0.882 Non-steroidal aromatase inhibitor for the treatment of hormonally-responsive breast cancer after
surgery
Glipizide -0.878 Anti-diabetic drug from the sulfonylurea class
Doxorubicin * -0.868 Treatment of a number of cancers including breast
Glibenclamide -0.867 Antidiabetic drug in a class of medications known as sulfonylureas
Tamoxifen * -0.759 Antagonist of the estrogen receptor in breast tissue
Results of cmap for compounds with expression signatures opposite those of loaded gene expression levels for breast cancer.
* Approved by the FDA for breast cancer
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Interestingly, studies show that women with increased
ADIPOQ concentrations possess 65% reduced risk for
breast cancer [27]. In another study, it has been shown
that patients with low ADIPOQ levels had a significantly
increased likelihood of cancer recurrence.
Unsupervised clustering analysis also revealed the gene
expression signatures to be associated with histologic
grade, age and triple negative status. This signature could
also be used for improving stratification of patients with
BC in this population. Further pathway analysis of differ-
entially regulated genes provides novel hypotheses under-
lying metastatic progression of BC. In addition, cmap
analysis can formulate novel therapeutics for BC, starting
from a cellular approach to investigating the effects of the
compound determined by cmap. It may be possible to
develop stratified therapy by combining both standard
chemotherapy and pathway-specific therapies.
ADIPOQ, an adipocyte secreted protein, was found to
one of the most downregulated gene in our analysis and
it’s lower expression levels have been shown to be asso-
ciated with obesity, insulin resistance, and type 2 diabetes
mellitus [33]. It has also been shown to be reduced in pre-
menopausal women with endometrial cancer, which is
tightly linked with obesity and insulin resistance. A case
control study found significantly inverse relationship of
serum ADIPOQ with BC [34].
Comparison of BC data from USA with KSA further
revealed distinct expression levels for LEP and other genes
involved in lipid metabolism [35]. In our analysis, glycero-
lipid metabolism was found to be a highly significantly
altered canonical pathway. However, comparative analysis
of these findings is different from the recent transcrip-
tomic profiles of BC from the USA data, as glycerolipid
metabolism was ranked 41st in the USA data [35]. In the
KSA samples, glycerolipid metabolism was one the most
overrepresented pathways, whereas, PPARa / RXRa acti-
vation pathway is the most disrupted one in the USA data.
To comprehend population differences in the severity
of BC, studies linking both genetic and environmental
factors and examining cases from different populations
are important. Researchers have been investigating issues
surrounding lifestyle, circadian rhythm, obesity, and
adverse exposures in an attempt to identify susceptibility
factors in initiating BC. Since diet and obesity contribute
to changes in circulating hormone levels, they both play a
key role in the development of BC. Understanding the
underlying genetics and complex interactions of lifestyle,
diet, and other known risk factors will remain a key area
of research.
The prevalence of obesity among Saudi patients adults
was 55.56% in comparison to 33.8% in USA adults, how-
ever combined obese and overweight percentage were
almost same with 68.0% in western and 73 % in Saudi BC
patients [36]. Obesity is primarily characterized by excess
fat storage, adipocyte mass, and increase in certain types
of lipids. Normally healthy women have 14–28% of fat
mass in the body, but it may increase up to 60–70% in
morbidly obese individuals [37]. Earlier white adipose tis-
sue function was assigned for purely an energy storage
tissue, however, recent finding has uncovered the endo-
crine and metabolic properties that has led to several
mechanisms implicated in how obesity drives cancer pre-
valence and cancer deaths. Many possible mechanisms
have been proposed to explain the increased risk of
breast cancer associated with obesity such as increased
lipids and lipid signaling, inflammatory responses, insulin
resistance, adipokines, altered immune responses, and
oxidative stress. Study had shown that cancer cells can
access lipids from neighboring adipocyte stores and can
directly use these transferred lipids as an energy source,
which in turn promotes tumor growth [38]. Thus, it is
critical to understand the physiological impact of obesity
on breast cancer development and progression. In recent
years, obesity has been identified as a significant modifi-
able increased risk factor for breast cancers among post-
menopausal women but is unrelated or inversely related
to risk among premenopausal women not in pre-meno-
pausal women [39-43]. A study examined obesity and
mortality from cancer in 495,477 US women, and found
that obese women had double the death rate (relative
risk, 2.12) than women with normal BMI (25 or less) [44].
Fat tissue of obese women are most important source
of estrogen after ovary, secreting higher level of estrogen
potentially leading to more rapid growth of estrogen-
responsive breast tumors [45]. Fat cells may also pro-
mote inflammation linked cancer through tumor growth
regulators and tumor necrotic factors. Obesity often
cause insulin resistance, which may promote the devel-
opment of breast cancer [46,47]. Adipose tissue secrete
TNF-a leading to inflamation promoting cancer. Fat
cells produce hormones, called adipokines, that may sti-
mulate or inhibit cell growth [48]. For example, adipo-
nectin, a down regulated gene in present study, has
been reported to be inhibitor for proliferetion and nega-
tive regulator of angiogenesis [37,49,50]. Further a sig-
nificant inverse correlation between serum adiponectin
levels and poor-prognosis breast cancer were confirmed.
Thus, low adiponectin in obese individuals could
increase risk of developing tumors with aggressive
angiogenesis [34,51].
Conclusions
This study described, to our knowledge, the first genome-
wide profiling of BC from Saudi ethnic females. Our analy-
sis reveals appropriate biological relevance and a number
of molecular pathways that may serve as targets for novel
therapeutics. Our finding of 73.3% obese vs 26.7% normal
weight clearly suggest that obesity increases the risk of
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breast cancer occurrence. Further studies are needed to
determine the relationship between lipid metabolism dys-
regulation and the mechanisms underlying BC. This study
may open new avenues of experimental strategies for
further examination in larger cohorts of all subtypes,
correlating ethnicity to molecular signature and life-style.
Methods
Patients and samples
The study was performed on female BC patients from the
KSA, diagnosed with invasive ductal carcinoma. The sam-
ples were collected from one of the three participating
Medical Centers in Jeddah, the KSA including King Abdu-
laziz University Hospital, King Faisal Specialist Hospital
and Research Center, and Bakshs Hospital, during years
2008-2011. For gene expression analysis, fresh tumor tis-
sue specimens were cut from fresh surgical resections
adjacent to the sites on which final histological diagnosis
was performed. Fresh normal breast specimens were
derived from surgically resected normal breast tissues.
Patients excluded from this study had at least one of the
following exclusion criteria: histopathological diagnosis
was not invasive ductal carcinoma; patient history, and
medical files, or specimens were not found. This left sam-
ples from 45 tumors available for transcriptomic analysis.
All collected tissue specimens were immediately placed in
RNALater (Invitrogen - Life Technologies, Grand Island,
NY) or RPMI 1640 medium (GIBCO, USA). Clinicopatho-
logical features such as age, tumor grade, tumor size, hor-
mone receptor status, lymph node involvement and
pathology reports were retrieved from the patients’ records
after obtaining all the relevant ethical approvals. The com-
plete histoclinical characteristics of the 45 BC patients are
summarized in Table 3. The average age in the present
cohort was 48 years, with a median of 47 years (range
between 27-80 years). Body mass index (BMI), a measure
of weight relative to height was used to estimate Normal
weight (≥18 -24.9 kg/m2 overweight (≥25-29.9 kg/m2) and
obesity (≥30 kg/m2).
Ethical approval
All patients included in the study provided written
informed consent. The study was reviewed and approved
by the Center of Excellence in Genomic Medicine
Research (CEGMR) ethical committee (approval number
08-CEGMR-02-ETH).
RNA extraction and array processing
Total RNA was extracted from fresh breast tissue speci-
mens with the Qiagen RNeasy Mini Kit (Qiagen, Hilden,
Germany) including an on-column DNAse treatment
according to manufacturer’s recommendations. Quality of
the purified RNA was verified on an Agilent 2100 Bioana-
lyzer (Agilent Technologies, Palo Alto, CA). Mean value of
Table 3 Clinicopathological characteristics of the





≤ 50 32 71
≥50 13 29
Age, mean (range) years 48 (27-80)
BMI (Kg/m2)
Obese (≥30 Kg/m2) 25 56
Over weight (≥25-29.9 Kg/m2) 8 18
Normal weight (≥18- 24.9 Kg/m2) 10 22




































Merdad et al. BMC Genomics 2015, 16(Suppl 1):S11
http://www.biomedcentral.com/1471-2164/16/S1/S11
Page 9 of 12
RNA integrity number (RIN) for all 50 processed samples
was 8.0. RNA concentrations were determined using a
NanoDrop ND-1000 spectrophotometer (NanoDrop
Technologies, Wilmington, DE). 300 ng of each RNA sam-
ple was processed according to the manufacturer`s recom-
mendation (Affymetrix, Santa Clara, CA, USA). After
fragmentation and labeling, the samples were hybridized
at 45°C for 17 hours to Human Gene 1.0 ST GeneChip
arrays (Affymetrix, Santa Clara, CA, USA). These arrays
are conceptually based on the Human Genome sequence
assembly UCSC hg18, NCBI Build 36 and interrogate with
a set of 764,885 probes 28,869 annotated genes.
Gene Expression Analysis
Affymetrix .CEL files and were imported to Partek Geno-
mics Suite version 6.5 (Partek Inc., MO, USA). The data
was normalized using RMA normalization. Principal com-
ponent analysis (PCA) was performed on all probes to
visualize high dimensional data. PCA was used to assess
quality control as well as overall variance in gene expres-
sion between the disease states. Analysis of Variance
(ANOVA) was applied on the complete data set and dif-
ferentially expressed gene list was then generated using an
FDR (Benjamini Hochberg) of 0.05 with 2 fold change cut
off. Unsupervised two dimensional average linkage hier-
archical clustering was performed using Spearman’s corre-
lation as a similarity matrix. The microarray data
generated in this study are in compliance with MIAME
(http://www.mged.org/Workgroups/MIAME/miame.html)
guidelines.
Functional and Pathway analysis
To define biological networks, interaction and functional
analysis among the differentially regulated genes in BC,
pathway analyses were performed using Ingenuity Path-
ways Analysis software (IPA) (Ingenuity Systems, Red-
wood City, CA). Statistically differentially expressed
dataset containing 1159 genes and their corresponding
probesets ID, Gene symbol, Entrez gene ID as clone
identifier, p-value and fold change values were uploaded
into the IPA. The functional/pathway analysis of IPA
identifies the biological functions and/or diseases and
pathways that are most significantly altered for the dif-
ferentially expressed gene set. The significance of the
connection between the expression data and the canoni-
cal pathway were calculated by ratio and/or Fisher’s
exact.
Connectivity Map analysis
The differentially expressed genes identified were analyzed
using the cmap in an effort to link genes associated with a
phenotype with potential drug molecules. Cmap analyzes
the correlation between our gene expression signature and
predefined signatures of therapeutic compounds. A ‘‘con-
nectivity score” (+1 to -1), signifying relative similarity to
our differentially expressed genes, was generated using a
metric based on the Kolmogorov-Smirnov statistic, as
described [21]. A compound with negative connectivity
scores represents compounds that potentially would
reverse the molecular phenotype.
Availability of supporting data
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